Pfizer
New York, NY
ROLE SUMMARY Migraine is a common, debilitating neurological disease affecting 40M people in the US. Surprisingly, less than half of the 19.5M people living with Migraine have been diagnosed, and fewer than half of those diagnosed are treated on Rx therapy. Pfizer’s product ZAVZPRET is the first intranasal calcitonin gene-related peptide (CGRP) monoclonal antibody indicated for the acute treatment of migraine attacks with or without aura. Following its launch in July 2023, ZAVZPRET has become the fastest growing acute non-oral product in the migraine space and continues to gain momentum. The ZAVZPRET Marketing Director will be accountable for supporting the team’s expansive medical education and peer to peer efforts, working closely with the HCP marketing team to drive ZAVZPRET-specific initiatives such as speaker programs, and the Nurtec ODT marketing team on portfolio-driven initiatives. The marketing director will also have the opportunity to support...